en.Wedoany.com Reported - A joint research project conducted by Rigaku Corporation, Shionogi & Co., Ltd., JEOL Ltd., and Meiji Pharmaceutical University has yielded a new discovery in the field of drug polymorphism, with the findings published in the international crystallography journal Crystal Growth & Design.

The research team has identified a new polymorph of indomethacin, designated as the κ-form. Indomethacin is a widely used analgesic and anti-inflammatory drug. Despite its long-standing market presence, the discovery of a new polymorph is extremely rare and holds significant importance for both crystallography and pharmaceutical research. Crystal polymorphism refers to the phenomenon where the same compound forms different crystal structures, leading to variations in properties such as solubility and stability, making it a critical research topic affecting drug quality and manufacturability.

This study employed the MicroED method for structural analysis, utilizing the fully integrated electron diffractometer XtaLAB Synergy-ED, jointly developed by Rigaku and JEOL. The newly discovered polymorph consists of extremely tiny crystals measuring less than one micrometer, making structural analysis difficult using traditional X-ray diffraction methods. By leveraging MicroED technology, the research team successfully elucidated the crystal structure of the new κ-form. Analysis of molecular arrangements within the crystal revealed intermolecular interactions that contribute to the stability of this polymorph. These results demonstrate the effectiveness of MicroED in detecting previously undetectable polymorphs and highlight its potential for improving drug quality and accelerating drug development.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com